IL17A and COVID-19: Studies show that COVID-19 is marked by dysregulation of myeloid cells9, and that critically ill patients have high serum concentrations of pro-inflammatory cytokines such as interleukins IL-6, IL-1β, IL-2, IL-8, IL-17, and tumor necrosis factor-α (TNF-α)10.